Skip to content

PECS I Block for Breast Subpectoral Implant Surgery

Analgesic Efficacy of the Pectoral Nerve Block Type 1 for Breast Subpectoral Implant Surgery: A Randomized Controlled Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02849236
Enrollment
56
Registered
2016-07-29
Start date
2016-10-16
Completion date
2020-07-31
Last updated
2020-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Postoperative

Keywords

PECS block,, pectoral block,, breast augmentation

Brief summary

Breast augmentation surgery can cause important postoperative pain, especially when bilateral subpectoral implants are used. The investigators hypothesized that a technique of regional analgesia, the pectoral nerve block type I (or PECS I block) would reduce pain within the first twenty-four hours and, in turn, morphine consumption and associated side effects. This is a randomized, controlled, double-blind study which compares intra and postoperative analgesia with or without PECS I block in breast surgery.

Interventions

DRUGRopivacaine (PECS bloc)

Ropivacaine 3.75mg/mL Injection of a local anesthetic between pectoral major and pectoral minor muscles

DRUGPlacebo

20 mL saline 0.9%

Sponsors

University Hospital, Lille
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Every female who will benefit of a bilateral subpectoral breast augmentation * Age more than 18 years * Social insured

Exclusion criteria

* refusal of the patient * Age less than 18 years * Inability to consent * History of thoracic surgery or breast implants * Pregnancy * Inability to use a patient controlled analgesia * Contraindication of the use of opioids or local anesthetics * Pathology of hemostasis, infection * Can not use a PCA * Patients under long-term opioids (WHO pain ladder 2 and 3) * Patient presenting neuropathic pain during the preoperative period (score greater than or equal to 4 to the DN4 questionnaire, or taking anti-epileptic or antidepressant treatments for neuropathic pain)

Design outcomes

Primary

MeasureTime frameDescription
Morphine consumptionDuring the first 24 postoperative hoursMorphine consumption by use of patient control analgesia within the first twenty-four hours after surgery.

Secondary

MeasureTime frameDescription
Post-operative nausea and/or vomitingDuring the first 24 postoperative hoursNumber of nausea and/or vomiting episodes in the twenty-four hours after surgery
Intra-operative opioids consumptionDuring procedure executionSufentanil consumption during anesthesia
Post-operative anti-emetic consumptionDuring the first 24 postoperative hoursConsumption of anti-emetic drugs after surgery
First administration of morphineDuring the first 24 postoperative hoursTime elapsed between tracheal extubation and first administration of morphine
4-point sedation scaleDuring the first two postoperative hoursusing WHO Sedation scale \- 0 = awake and alert /- 1 = quietly awake / - 2 = asleep but easily roused / - 3 = deep sleep
Aldrete scoreDuring the first two postoperative hoursAldrete Score is a medical scoring system for the measurement of recovery after anesthesia (post anesthesia) which includes activity, respiration, consciousness, blood circulation and color.
Time physiological function recoveryDuring the first six postoperative hours after tracheal extubationAbility to drink, to eat, to urinate, to walk
Post-operative painDuring the first 24 postoperative hoursEvaluation of post-operative pain with a digital scale from 0 to 10 in the first twenty four hours after surgery

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026